상세 보기
Pretreatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs
- Jang, Tyng-Yuan;
- Dai, Chia-Yen;
- Huang, Chung-Feng;
- Liang, Po-Cheng;
- Jun, Dae Won;
- ... Yoon, Eileen L.;
- ... An, Jihyun;
- 외 36명
WEB OF SCIENCE
3SCOPUS
5초록
Elevated serum gamma-glutamyl transferase (GGT) levels are associated with chronic hepatitis B (CHB)-related hepatocellular carcinoma. However, their role in predicting mortality in patients with CHB treated with nucleotide/nucleoside analogs (NAs) remains elusive. Altogether, 2843 patients with CHB treated with NAs were recruited from a multinational cohort. Serum GGT levels before and 6 months (Month-6) after initiating NAs were measured to explore their association with all-cause, liver-related, and non-liver-related mortality. The annual incidence of all-cause mortality was 0.9/100 person-years over a follow-up period of 17,436.3 person-years. Compared with patients who survived, those who died had a significantly higher pretreatment (89.3 vs. 67.4 U/L, p = 0.002) and Month-6-GGT levels (62.1 vs. 38.4 U/L, p < 0.001). The factors associated with all-cause mortality included cirrhosis (hazard ratio [HR]/95% confidence interval [CI]: 2.66/1.92–3.70, p < 0.001), pretreatment GGT levels (HR/CI: 1.004/1.003–1.006, p < 0.001), alanine aminotransferase level (HR/CI: 0.996/0.994–0.998, p = 0.001), and age (HR/CI: 1.06/1.04–1.07, p < 0.001). Regarding liver-related mortality, the independent factors included cirrhosis (HR/CI: 4.36/2.79–6.89, p < 0.001), pretreatment GGT levels (HR/CI: 1.006/1.004–1.008, p < 0.001), alanine aminotransferase level (HR/CI: 0.993/0.990–0.997, p = 0.001), age (HR/CI: 1.03/1.01–1.05, p < 0.001), and fatty liver disease (HR/CI: 0.30/0.15–0.59, p = 0.001). Pretreatment GGT levels were also independently predictive of non-liver-related mortality (HR/CI: 1.003/1.000–1.005, p = 0.03). The results remained consistent after excluding the patients with a history of alcohol use. A dose-dependent manner of <25, 25–75, and >75 percentile of pretreatment GGT levels was observed with respect to the all-cause mortality (trend p < 0.001). Pretreatment serum GGT levels predicted all-cause, liver-related, and non-liver-related mortality in patients with CHB treated with NAs.
키워드
- 제목
- Pretreatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs
- 저자
- Jang, Tyng-Yuan; Dai, Chia-Yen; Huang, Chung-Feng; Liang, Po-Cheng; Jun, Dae Won; Jung, Jang Han; Toyoda, Hidenori; Wang, Chih-Wen; Yuen, Man-Fung; Cheung, Ka Shing; Yasuda, Satoshi; Kim, Sung Eun; Yoon, Eileen L.; An, Jihyun; Enomoto, Masaru; Kozuka, Ritsuzo; Chuma, Makoto; Nozaki, Akito; Ishikawa, Toru; Watanabe, Tsunamasa; Atsukawa, Masanori; Arai, Taeang; Hayama, Korenobu; Ishigami, Masatoshi; Cho, Yong Kyun; Ogawa, Eiichi; Kim, Hyoung Su; Shim, Jae-Jun; Uojima, Haruki; Jeong, Soung Won; Ahn, Sang Bong; Takaguchi, Koichi; Senoh, Tomonori; Buti, Maria; Vargas-Accarino, Elena; Abe, Hiroshi; Takahashi, Hirokazu; Inoue, Kaori; Huang, Jee-Fu; Chuang, Wan-Long; Yeh, Ming-Lun; Nguyen, Mindie H.; Yu, Ming-Lung
- 발행일
- 2024-02
- 유형
- Article; Early Access
- 권
- 40
- 호
- 2
- 페이지
- 188 ~ 197